Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation

BACKGROUND: Although many studies have defined mechanisms of resistance to EGFR‐TKIs, acquired resistance remains the major limitation of monotherapy with EGFR‐TKIs. METHODS: Cell viability was analyzed using a Cell Counting Kit‐8 (CCK‐8) assay. EGFR T790M mutation was sequenced on a HiSeq 4000 plat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thorac Cancer
Autors principals: Lian, Zengzhi, Du, Wenwen, Zhang, Yang, Fu, Yulong, Liu, Ting, Wang, Anqi, Cai, Tingting, Zhu, Jianjie, Zeng, Yuanyuan, Liu, Zeyi, Huang, Jian‐an
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons Australia, Ltd 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327692/
https://ncbi.nlm.nih.gov/pubmed/32433828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13485
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars